In:
The Laryngoscope, Wiley, Vol. 116, No. 7 ( 2006-07), p. 1168-1171
Abstract:
Objectives: Botulinum toxin type A (BtxA) has been reported to be feasible in chronic neuropathic pain after neck dissection. The impact of the dose on the outcome has not been investigated yet. Study Design: Twenty‐three patients with neuropathic pain after neck dissection were selected for an open and prospective phase II trial. Methods: In the low‐dose group (n = 13), a concentration of 10 mouse units (MU)/0.1 mL saline and in the high‐dose‐group (n = 10), a concentration of 20 MU/0.1 mL saline were injected subcutaneously. Pain and quality of life were assessed at day 0 and day 28, respectively, by visual analog scales (VAS) and European Organization for Research and Treatment of Cancer (EORTC) quality‐of‐life core and EORTC quality‐of‐life head and neck module questionnaires. Results: Patients in the low‐dose group showed a significant pain reduction (VAS) from 4.3 at day 0 to 3.0 at day 28 ( P 〈 .05). The mean pain VAS values in the high‐dose group did not improve significantly. No serious adverse events were observed. There were trends toward improvement in quality of life in the low‐dose group. Conclusions: BtxA in a low concentration seems to be a useful therapeutic option in chronic neuropathic pain of the neck and shoulder after neck dissection.
Type of Medium:
Online Resource
ISSN:
0023-852X
,
1531-4995
DOI:
10.1097/01.mlg.0000217797.05523.75
Language:
English
Publisher:
Wiley
Publication Date:
2006
detail.hit.zdb_id:
2026089-1
